Plazomicin
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Plazomicin: From Gram-Negative Bacterial Infections to Gonococcal Urethritis
One-Sentence Summary
Plazomicin is a next-generation aminoglycoside antibiotic with activity against certain Gram-negative pathogens, but detailed original indication and mechanism-of-action data are not currently on file for this drug. The TxGNN model predicts it may be effective for Gonococcal Urethritis, but currently 0 clinical trials and 0 publications support this direction — this is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication or license data on file |
| Predicted New Indication | Gonococcal Urethritis |
| TxGNN Prediction Score | 99.64% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Plazomicin. Based on the information that is available, Plazomicin is a next-generation aminoglycoside antibiotic understood to act against certain Gram-negative bacteria, likely through inhibition of the 30S ribosomal subunit and disruption of bacterial protein synthesis — the mechanism shared by the aminoglycoside class.
The predicted link to gonococcal urethritis (caused by Neisseria gonorrhoeae, a Gram-negative diplococcus) is mechanistically plausible in principle, since aminoglycosides can have activity against Gram-negative organisms. However, the current standard of care for gonococcal infection is ceftriaxone, and aminoglycosides are not a first-line or guideline-supported treatment for this indication. Without confirmed original-indication data or MOA specifics for Plazomicin, and without any in vitro susceptibility data against N. gonorrhoeae, this connection cannot be confirmed and should be treated as a hypothesis generated purely from knowledge-graph structure rather than an established pharmacological rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by TxGNN model scoring (Evidence Level L5) with zero clinical trials and zero publications, and the drug currently has no approved indication or MOA data on file. The proposed mechanistic rationale is weak and conflicts with the established standard of care (ceftriaxone) for gonococcal infection.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for Plazomicin (via DrugBank API)
- TFDA/FDA label warnings and contraindications (currently blocking safety review — flagged as Blocking data gap)
- In vitro susceptibility data of Plazomicin against Neisseria gonorrhoeae
- Any preclinical, case-report, or observational evidence before advancing beyond model-only prediction stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.